Overview of Breast Cancer Treatment and Reconstruction for Primary Care Providers

Carlson, Nicole S.; King, Joyce E.

doi:10.1111/j.1542-2011.2012.00249.x

Cited by 8 publications

(11 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer is generally described by the type, stage, and hormone receptor status. Stages of breast cancer are 0 (noninvasive), I and II (early invasive), III (locally advanced invasive), and IV (metastatic or recurrent) . The National Cancer Institute defines early‐stage breast cancer as “breast cancer that has not spread beyond the breast or the axillary lymph nodes.…”

Section: Overview Of Breast Cancermentioning

confidence: 99%

“…Decisions for treatment are based on input from breast cancer specialists and the individual woman's preferences for treatment. An overview of breast cancer staging and prognosis is presented in Table …”

Section: Overview Of Breast Cancermentioning

confidence: 99%

“…Most women with early‐stage breast cancer choose breast‐conserving surgery followed by radiation. Bilateral mastectomy is considered if a woman has additional risk factors, such as BRCA mutations or a strong family history of breast cancer . Table presents an overview of treatment of breast cancer by stage .…”

Section: Overview Of Breast Cancermentioning

confidence: 99%

“…Bilateral mastectomy is considered if a woman has additional risk factors, such as BRCA mutations or a strong family history of breast cancer . Table presents an overview of treatment of breast cancer by stage . Follow‐up for early‐stage breast cancer after treatments and procedures is based on National Comprehensive Cancer Network (NCCN) Guidelines …”

Section: Overview Of Breast Cancermentioning

confidence: 99%

See 3 more Smart Citations

Filling the Gap for Early‐Stage Breast Cancer Follow‐Up: An Overview for Primary Care Providers

Bond-Bero¹

2016

J Midwife Womens Health

View full text Add to dashboard Cite

Earlier detection and newer treatments now make breast cancer highly survivable, and breast cancer survivors are the largest female cancer survivor group in the United States. With earlier detection, more women are being diagnosed with early-stage breast cancer and need follow-up care. With the increasing number of breast cancer survivors, there is a projected shortage in the workforce of oncology specialists to care for these women. The American Society of Clinical Oncology recommends that breast cancer follow-up care can be provided by an oncologist or primary care provider, as long as the primary care provider has spoken to the oncologist about appropriate follow-up care. Several studies have shown that primary care providers and oncologists have comparable outcomes for follow-up care of women with early-stage breast cancer. The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) are considered the gold standard for breast cancer treatment and follow-up. These guidelines are clear and straightforward. Using knowledge of the NCCN Guidelines, primary care providers can fill the gap for follow-up care of women with early-stage breast cancer.

show abstract

Section: Overview Of Breast Cancermentioning

confidence: 99%

Section: Overview Of Breast Cancermentioning

confidence: 99%

Section: Overview Of Breast Cancermentioning

confidence: 99%

Section: Overview Of Breast Cancermentioning

confidence: 99%

See 2 more Smart Citations

Filling the Gap for Early‐Stage Breast Cancer Follow‐Up: An Overview for Primary Care Providers

Bond-Bero¹

2016

J Midwife Womens Health

View full text Add to dashboard Cite

show abstract

“…At stage I, II, and III, the cancer may be defined by the size of the tumors and the area that the cancer cells have spread, such as the chest wall, skin, or the lymph nodes surrounding the breast. At the advanced or metastatic stage (stage IV), the cancer cells have metastasized to other organs or lymph nodes that are further away from the breast [5,6]. Breast cancer is a heterogeneous disease, as there are many distinct genes being overexpressed and acting as key players in the progression of the breast cancer cells [7].…”

Section: Introductionmentioning

confidence: 99%

Oncogenic Signaling in Tumorigenesis and Applications of siRNA Nanotherapeutics in Breast Cancer

Kamaruzman

Aziz

Poh

et al. 2019

Cancers

View full text Add to dashboard Cite

Overexpression of oncogenes and cross-talks of the oncoproteins-regulated signaling cascades with other intracellular pathways in breast cancer could lead to massive abnormal signaling with the consequence of tumorigenesis. The ability to identify the genes having vital roles in cancer development would give a promising therapeutics strategy in combating the disease. Genetic manipulations through siRNAs targeting the complementary sequence of the oncogenic mRNA in breast cancer is one of the promising approaches that can be harnessed to develop more efficient treatments for breast cancer. In this review, we highlighted the effects of major signaling pathways stimulated by oncogene products on breast tumorigenesis and discussed the potential therapeutic strategies for targeted delivery of siRNAs with nanoparticles in suppressing the stimulated signaling pathways.

show abstract

PDP1 promotes the progression of breast cancer through STAT3 pathway

Wang,

Dang,

Qiao

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

This study aimed to investigate the expression pattern and mechanisms of Pyruvate Dehydrogenase Phosphatase Catalytic Subunit 1 (PDP1) in the progression of breast cancer (BC). PDP1, known for its involvement in cell energy metabolism, was found to be overexpressed in BC tissues. Notably, low PDP1 expression aligns with improved overall survival (OS) in BC patients. In this study, we found that PDP1 was overexpressed among BC tissues and low PDP1 expression showed a better prognosis for the patients with BC. PDP1 knockdown suppressed cell amplification and migration and triggered cell apoptosis in BC cells. In vivo assessments through a xenograft model unveiled the pivotal role and underlying mechanisms of PDP1 knockdown. RNA sequencing and kyoto encyclopedia of genes and genomes analysis of RNAs from PDP1 knockdown and normal MCF7 cells revealed 1440 differentially expressed genes, spotlighting the involvement of the JAK/STAT3 signaling pathway in BC progression. Western blot results implied that PDP1 knockdown led to a loss of p‐STAT3, whereas overexpression of PDP1 induced the p‐STAT3 expression. Cell counting kit‐8 assay showed that PDP1 overexpression significantly raised MDA‐MB‐231 and MCF7 cell viability while STAT3 inhibitor S3I‐201 recovered the cell growth to normal level. To summarize, PDP1 promotes the progression of BC through STAT3 pathway by regulating p‐STAT3. The findings contribute to understanding the molecular mechanisms underlying BC progression, and opening avenues for targeted therapeutic approaches.

show abstract

Overview of Breast Cancer Treatment and Reconstruction for Primary Care Providers

Cited by 8 publications

References 72 publications

Filling the Gap for Early‐Stage Breast Cancer Follow‐Up: An Overview for Primary Care Providers

Filling the Gap for Early‐Stage Breast Cancer Follow‐Up: An Overview for Primary Care Providers

Oncogenic Signaling in Tumorigenesis and Applications of siRNA Nanotherapeutics in Breast Cancer

PDP1 promotes the progression of breast cancer through STAT3 pathway

Contact Info

Product

Resources

About